WEREWOLF THERAPEUTICS, INC. Increase (Decrease) in Other Receivables
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Increase (Decrease) in Other Receivables of $0 for the 12-month period ending 2025-12-31, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2025-12-31 was $0.00.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2025-09-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2025-06-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2025-03-31 was $0.00.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2023 was -$5.58M, a 180.51% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2022 was $6.93M.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2021 was $0.00.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 S-4 · filed 2026-09-22 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | -$464.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | -$464.00K derived: sum of 3 quarters · filed 2026-09-22 | -$545.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$464.00K derived: sum of 2 quarters · filed 2026-09-22 | -$545.00K derived: sum of 3 quarters · filed 2026-09-22 | -$775.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | -$464.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$545.00K derived: sum of 2 quarters · filed 2026-09-22 | -$775.00K derived: sum of 3 quarters · filed 2026-09-22 | -$1.35M S-4 · filed 2026-09-22 |
| 2024-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$311.00K derived: sum of 2 quarters · filed 2025-11-04 | -$886.00K 10-Q · filed 2025-11-04 | -$5.45M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$805.00K 10-Q · filed 2025-08-14 | -$5.37M derived: sum of 3 quarters · filed 2025-08-14 | -$6.38M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$575.00K 10-Q · filed 2025-05-08 | -$5.14M derived: sum of 2 quarters · filed 2025-05-08 | -$6.15M derived: sum of 3 quarters · filed 2025-05-08 | -$5.48M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$5.58M derived: sum of 2 quarters · filed 2025-03-11 | -$4.91M derived: sum of 3 quarters · filed 2025-03-11 | -$5.58M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$344.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.02M 10-Q · filed 2024-11-07 | $1.61M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $672.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.00K 10-Q · filed 2024-08-08 | $2.63M derived: sum of 3 quarters · filed 2024-08-08 | $4.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$673.00K 10-Q · filed 2024-05-03 | $1.96M derived: sum of 2 quarters · filed 2024-05-03 | $4.04M derived: sum of 3 quarters · filed 2024-05-03 | $6.25M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $4.71M derived: sum of 2 quarters · filed 2024-03-07 | $6.93M derived: sum of 3 quarters · filed 2024-03-07 | $6.93M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.30M derived: sum of 2 quarters · filed 2023-11-14 | $4.30M 10-Q · filed 2023-11-14 | $4.30M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.22M 10-Q · filed 2023-08-10 | $2.22M derived: sum of 3 quarters · filed 2023-08-10 | $2.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |